Tag Archives: hypertrophic cardiomyopathies

ACC 2022

ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

Roughly 50% of hypertrophic cardiomyopathies (HCM) are obstructive, and of this percentage, most of symptoms can be attributed to this condition. Historically, it has been treated with non-specific drugs such as betablockers or calcium blockers.  There is an alternative treatment, septal reduction therapy (SRT), done either by surgery myectomy and alcohol septal ablation, both normally done in

Top